Tag Archives: Justin Zelin

BTIG Remains a Buy on MEI Pharma (MEIP)

In a report issued on September 2, Justin Zelin from BTIG maintained a Buy rating on MEI Pharma (MEIP – Research Report), with a price target of $9.00. The company’s shares closed last Friday at $2.89. According to TipRanks.com, Zelin

BTIG Thinks Surface Oncology’s Stock is Going to Recover

BTIG analyst Justin Zelin maintained a Buy rating on Surface Oncology (SURF – Research Report) on June 4 and set a price target of $17.00. The company’s shares closed last Friday at $5.70, close to its 52-week low of $4.95.

B.Riley Financial Sticks to Its Buy Rating for Heat Biologics (HTBX)

B.Riley Financial analyst Justin Zelin maintained a Buy rating on Heat Biologics (HTBX – Research Report) on October 27 and set a price target of $4.00. The company’s shares closed last Wednesday at $1.11. According to TipRanks.com, Zelin is a

B.Riley Financial Remains a Buy on Krystal Biotech (KRYS)

B.Riley Financial analyst Justin Zelin reiterated a Buy rating on Krystal Biotech (KRYS – Research Report) today and set a price target of $100.00. The company’s shares closed last Tuesday at $41.68. According to TipRanks.com, Zelin is a 1-star analyst

Mustang Bio (MBIO) Received its Third Buy in a Row

After Oppenheimer and H.C. Wainwright gave Mustang Bio (NASDAQ: MBIO) a Buy rating last month, the company received another Buy, this time from B.Riley Financial. Analyst Justin Zelin reiterated a Buy rating on Mustang Bio today and set a price

B.Riley Financial Thinks Abeona Therapeutics’ Stock is Going to Recover

In a report released today, Justin Zelin from B.Riley Financial reiterated a Buy rating on Abeona Therapeutics (ABEO – Research Report), with a price target of $2.00. The company’s shares closed last Tuesday at $1.22, close to its 52-week low